TSVT Stock Overview
A cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
2seventy bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.27 |
| 52 Week High | US$12.69 |
| 52 Week Low | US$1.54 |
| Beta | 1.87 |
| 1 Month Change | 0.35% |
| 3 Month Change | -21.51% |
| 1 Year Change | -64.21% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -68.99% |
Recent News & Updates
Recent updates
Downgrade: Here's How Analysts See 2seventy bio, Inc. (NASDAQ:TSVT) Performing In The Near Term
May 11
2seventy Bio: Maximizing ABECMA's Potential To Fuel A Turnaround
Apr 03These Analysts Just Made A Massive Downgrade To Their 2seventy bio, Inc. (NASDAQ:TSVT) EPS Forecasts
Mar 072seventy bio, Inc. (NASDAQ:TSVT) Held Back By Insufficient Growth Even After Shares Climb 49%
Feb 06Here's Why We're Watching 2seventy bio's (NASDAQ:TSVT) Cash Burn Situation
Jan 172seventy bio, Inc. (NASDAQ:TSVT) Shares Fly 44% But Investors Aren't Buying For Growth
Dec 13Industry Analysts Just Made A Dazzling Upgrade To Their 2seventy bio, Inc. (NASDAQ:TSVT) Revenue Forecasts
May 05Industry Analysts Just Upgraded Their 2seventy bio, Inc. (NASDAQ:TSVT) Revenue Forecasts By 12%
Mar 212seventy bio, Inc. (NASDAQ:TSVT) Just Reported Annual Earnings And Analysts Are Lifting Their Estimates
Mar 19We're Keeping An Eye On 2seventy bio's (NASDAQ:TSVT) Cash Burn Rate
Oct 042seventy Bio: This Spinoff In The CAR-T Space Is Attractive
Sep 082seventy bio Prospects
Aug 23Time To Worry? Analysts Just Downgraded Their 2seventy bio, Inc. (NASDAQ:TSVT) Outlook
Aug 122seventy bio GAAP EPS of -$2.02 misses by $0.09, revenue of $13.48M misses by $3.04M
Aug 10Shareholder Returns
| TSVT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.5% | -1.9% | -0.3% |
| 1Y | -64.2% | 7.4% | 25.6% |
Return vs Industry: TSVT underperformed the US Biotechs industry which returned 7.4% over the past year.
Return vs Market: TSVT underperformed the US Market which returned 25.6% over the past year.
Price Volatility
| TSVT volatility | |
|---|---|
| TSVT Average Weekly Movement | 13.0% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: TSVT's share price has been volatile over the past 3 months.
Volatility Over Time: TSVT's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | 274 | Chip Baird | www.2seventybio.com |
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company’s products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company.
2seventy bio, Inc. Fundamentals Summary
| TSVT fundamental statistics | |
|---|---|
| Market cap | US$231.84m |
| Earnings (TTM) | -US$223.22m |
| Revenue (TTM) | US$71.20m |
3.1x
P/S Ratio-1.0x
P/E RatioIs TSVT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TSVT income statement (TTM) | |
|---|---|
| Revenue | US$71.20m |
| Cost of Revenue | US$29.63m |
| Gross Profit | US$41.57m |
| Other Expenses | US$264.79m |
| Earnings | -US$223.22m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.34 |
| Gross Margin | 58.39% |
| Net Profit Margin | -313.51% |
| Debt/Equity Ratio | 0% |
How did TSVT perform over the long term?
See historical performance and comparison